AIM ImmunoTech CEO and President Thomas K. Equels acquires $6,550 in common shares
AIM•AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 50,000 common shares at $0.131 each, increasing his direct beneficial ownership to 436,095 shares.




